Ginkgo Bioworks Holdings, Inc. — Form 8-K Summary
Business context and reporting period
Ginkgo filed this Current Report on July 25, 2022, regarding events occurring July 24, 2022. The filing reports Ginkgo’s agreement to acquire Zymergen Inc. through a merger. Zymergen would survive as a wholly owned subsidiary of Ginkgo. This is a transaction filing, not a periodic financial report, and does not provide current-period operating results.
Transaction terms and key financial considerations
- Zymergen stockholders will receive 0.9179 shares of Ginkgo Class A common stock for each Zymergen common share, plus cash in lieu of fractional shares.
- In-the-money Zymergen options will be converted into Ginkgo Class A shares based on the transaction value and the Ginkgo share price; out-of-the-money or at-the-money options will be cancelled without consideration.
- Vested Zymergen restricted stock units will be converted into the merger consideration. Unvested awards will generally convert into Ginkgo restricted stock units with substantially equivalent vesting terms.
- The filing does not provide a fixed dollar transaction value, total shares to be issued, revenue, profit, cash flow, margins, debt, or liquidity metrics.
Material changes versus the prior comparable period
No comparable-period financial information is presented. The material change is the announced proposed acquisition of Zymergen and the related potential issuance of Ginkgo Class A shares.
Conditions, timing, outlook, and risks
- Closing requires, among other conditions, approval by Zymergen stockholders, applicable antitrust clearances, effectiveness of Ginkgo’s Form S-4 registration statement, NYSE approval for the issued shares, absence of legal restraints, and satisfaction of customary representations and covenants.
- Ginkgo has an additional closing condition related to specified Zymergen real-estate costs and litigation exposure exceeding an aggregate $25 million threshold.
- The merger agreement may be terminated if not completed by January 24, 2023, subject to two potential three-month extensions when specified conditions are met.
- Zymergen may owe Ginkgo a $10 million termination fee in specified circumstances, including accepting a superior proposal or materially breaching its no-shop obligations. Ginkgo may owe Zymergen a $10 million termination fee only in specified circumstances involving failure to obtain regulatory approvals after other closing conditions are satisfied.
- Stockholders representing approximately 40% of Zymergen’s outstanding shares entered into voting agreements supporting the merger.
- Management’s anticipated synergies, value creation, effects on future results, and combined-company indebtedness are forward-looking and not quantified in the filing.
- Key risks include failure or delay in regulatory approvals, inability to complete or integrate the acquisition, failure to realize synergies, litigation, loss of personnel or business relationships, transaction-related distractions, and adverse market or operating effects.
Important facts for investors to verify
- Review the definitive merger agreement and any omitted schedules, particularly provisions concerning liabilities, litigation, real estate, termination rights, and closing conditions.
- Verify the final exchange ratio economics, Ginkgo share price used for award conversions, and the total number of Ginkgo shares issued at closing.
- Monitor the Form S-4, Zymergen proxy statement/prospectus, stockholder approval, antitrust reviews, and NYSE listing approval.
- Assess Zymergen’s financial condition, debt, cash needs, litigation exposure, and integration requirements using subsequent SEC filings.
- Do not treat the merger agreement’s representations, warranties, or forward-looking statements as independently verified factual conditions.